Breast cancer affects more than 192 000 (1) women in the United States every year, up to 40% of whom require a mastectomy (2). For some, the loss of a breast is devastating, and breast reconstruction is offered to improve outcomes (3,4).
Background
Breast reconstruction after mastectomy for cancer requires accurate evaluation to inform evidence-based participatory decision making, but the standards of outcome reporting after breast reconstruction have not previously been considered.
Methods
We used extensive searches to identify articles reporting surgical outcomes of breast reconstruction. We extracted data using published criteria for complication reporting modified to reflect reconstructive practice. Study designs included randomized controlled trials, cohort studies, and case series. The Cochrane Risk of Bias tool was used to critically appraise all study designs. Other criteria used to assess the studies were selection and funding bias, statistical power calculations, and institutional review board approval. Wilcoxon signed rank tests were used to compare the breadth and frequency of study outcomes, and x 2 tests were used to compare the number of studies in each group reporting each of the published criteria. All statistical tests were two-sided.
English, up to and including March 2009. Studies published before January 1995 were excluded to restrict the review to evaluations of current practice. Abstracts and conference reports were not included because of incomplete information. Duplicate records were excluded, and the titles and abstracts of the remaining citations were screened for eligibility by one reviewer (S. Potter) using predetermined selection criteria defined below. The reference lists of retrieved articles were manually searched to identify additional potentially relevant studies.
Selection of Articles
Randomized controlled trials (RCTs) and nonrandomized studies reporting at least one surgical complication of breast reconstruction surgery were included. Nonrandomized studies were required to include at least 100 women to focus the review on studies that would be likely to influence practice. Surgical complications were defined as any adverse event identified by a health-care professional, which occurred as a direct result of the reconstructive procedure, whether or not additional interventions were required. Articles reporting exclusively on patient-reported outcomes were excluded.
Articles describing all types of primary breast reconstruction surgery performed after a total mastectomy for breast cancer or preinvasive disease in women aged 18 years or older were eligible. Articles evaluating chest wall reconstruction for recurrent disease, volume replacement following breast conservation, and prophylactic surgery were excluded. Articles were screened for inclusion by one reviewer (S. Potter) and uncertainties discussed with the senior author (J. M. Blazeby).
Data Extraction
We modified published criteria (8) for the evaluation of surgical outcome reporting to reflect reconstructive practice. Specific modifications included the exclusion of mortality reporting and the combination of inpatient and outpatient assessments of morbidity. We therefore assessed whether each study reported data on the following: 1) prospective or retrospective accrual of data, 2) duration of follow-up, 3) proportion of complications defined, 4) reporting of both total and 5) procedure-specific complications, 6) grading of complication severity, 7) length of stay, and 8) whether the analysis was adjusted for risk factors such as smoking or radiotherapy.
In addition, the frequency with which each surgical complication was reported and defined in each article was recorded. Reported definitions of surgical complications were summarized. Review of included studies identified more than 100 different surgical complications following breast reconstruction surgery. For pragmatic reasons, to be included in the detailed analysis of complication reporting, a specific complication needed to be reported in at least 20% of the articles. Each factor was independently assessed by two authors (S. Potter and A. Brigic), and discrepancies were resolved by discussion with the senior author (J. M. Blazeby).
Critical Appraisal
Studies were appraised according to study design. Nonrandomized studies were categorized as cohort studies if a comparison was made between groups of patients undergoing breast reconstruction and as case series if no comparison was made.
RCTs were evaluated using the Cochrane Risk of Bias tool (13) , which included assessment of 1) adequacy of sequence generation, 2) allocation concealment, 3) blinding of outcome assessors, 4) selective outcome reporting, 5) completeness of outcome data, and 6) other sources of bias such as patient selection and funding bias. Selective outcome reporting was assessed by comparing the breadth and frequency of outcomes stated in the "Methods" and "Results" of the article. If the discrepancy between the number of prespecified and reported outcomes was more than one, the study was considered to be at risk of selective outcome reporting. The completeness of outcome data was determined by assessing the reporting of patient attrition. Data from studies failing to account for patient attrition were considered incomplete. We also identified two additional potential sources of bias, including selection bias and bias resulting from industry funding of research. Selection bias was evaluated by assessing whether studies reported clear inclusion and exclusion criteria or included consecutive patients. Finally, funding bias was assessed by determining whether included studies reported funding sources.
Applicable components of the Cochrane Risk of Bias tool (13) were also used to evaluate cohort studies and case series. Although developed for RCTs, issues addressed within the tool, including blinding, reporting of incomplete outcome data, and selective outcome reporting, were also considered to be relevant to nonrandomized studies. Thus, cohort and case series studies were assessed like RCTs, but only longitudinal studies were assessed for
CONT E X T S A N D C A V E A T S

Prior knowledge
Decisions by both patients and physicians about breast reconstruction after mastectomy depend on current knowledge of surgical outcomes, but the quality of outcome reporting from surgical studies has not been evaluated.
Study design
Reporting of outcomes, complications, and study designs was examined in a systematic review of clinical trials, cohort studies, and case series that reported on various techniques of breast reconstructive surgery.
Contribution
Outcome reporting for breast reconstruction is inconsistent and lacks methodological rigor. There were disparities between methods and results in the numbers of complications reported, and information on duration of follow-up and risk factors for adverse outcomes was frequently omitted.
Implications
The development of a core outcome set for breast reconstruction is needed to standardize outcome reporting and to improve study comparability and the information available to both patients and surgeons.
Limitations
The review was restricted to randomized controlled trials and large cohort studies and case series in English, so potentially useful information from smaller or non-English language studies may have been missed.
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completeness of outcome data. Selection and funding bias were also assessed. The risk of selection bias was evaluated by determining whether studies included consecutive patients, and potential funding bias was assessed by evaluating whether studies reported their funding source.
Finally, we developed two additional criteria that were evaluated in all studies. These included the presence of a statistical power calculation to determine whether authors had considered the number of patients required to address their research question and the reporting of institutional review board approval as an indicator of study peer review. Each of these factors was assessed by two reviewers (S. Potter and A. Brigic), and any discrepancies were resolved by discussion with the senior author (J. M. Blazeby).
Statistical Analysis
Data were compared according to study design. Wilcoxon signed rank tests were used to compare the breadth and frequency of outcomes reported in the methods and results sections of each study. We used x 2 tests to compare the number of studies in each group reporting each of the evaluated criteria (8) . All statistical tests were two-sided. STATA Version 11 (www.stata.com) was used for all analyses.
Results
Included Studies
From the 4921 citations initially screened, 134 primary studies (n = 42 106) reporting surgical outcomes were included: 11 (8.2%) RCTs (n = 812), 74 (55.2%) cohort studies (n = 26 486), and 49 (36.6%) case series (n = 14 808) ( Figure 1 and Tables 1-3) .
One RCT compared outcomes of different procedure types (pedicled and free transverse rectus abdominis myocutaneous flap) (14) . Ten RCTs compared the impact of smaller procedure modifications on outcome, including the use of different types of implants (n = 2) (15, 24) or expander port positions (n = 1) (17); different methods for reducing seroma formation (n = 3) (16, 20, 23) ; the impact of dividing the humeral insertion of the outcome of the latissimus dorsi flap (19) ; the effect of using different recipient vessels in microvascular flap reconstruction (22) ; the outcome of skin-sparing mastectomy performed with either conventional diathermy or high-frequency radiosurgery (21) and, finally, complication rates with and without neoadjuvant systemic therapy (18) ( Table 1) Eight of the cohort studies were prospective, and 66 were retrospective ( Table 2 ). Nineteen studies compared types of breast reconstruction (25, 26, 28, 37, 39, 44, 58, 59, 64, 67, (70) (71) (72) 74, 78, 81, 83, 87, 93) , 22 assessed the impact of risk factors such as smoking and obesity on outcomes (29, 38, 42, 45, (47) (48) (49) (50) 52, (61) (62) (63) 65, 66, 68, 73, 76, 82, 85, 90, 94, 98) , 17 evaluated the impact of radiotherapy (27, 30, 31, 33, 34, 36, 40, 41, 43, 53, 69, 86, 89, 91, (95) (96) (97) , and 17 assessed the impact of procedure modifications, including the use of different breast implants or different recipient vessels for microvascular breast reconstruction (32, 35, 46, 51, (54) (55) (56) (57) 60, 75, 77, 79, 80, 84, 88, 92) (Table 2 ).
There were 11 prospective and 38 retrospective case series (Table 3) . Of these, 24 reported outcomes of implant-based reconstruction (101) (102) (103) (104) (105) 108110, 116123, 126, 129, 131, 135, 137, 138, 143, 146) , 16 assessed autologous flaps (100, 106, 107, (111) (112) (113) (114) (115) 124, 125, 127, 130, 132, 139, 140, 144) , nine evaluated the outcome of skin or nipple sparing mastectomy (128, 133, 134, 136, 141, 142, 145, 147) , and one assessed the impact of complications on patient satisfaction without comparing study groups (99) ( Table 3) .
Critical Appraisal
Of the 11 RCTs, two studies (18.2%) reported robust methods for random sequence generation (16, 23) and adequate allocation concealment (18, 23) (Table 4 ). Three RCTs (27.3%) reported who was responsible for assessing outcome, but only one of these was adequately blinded (23) . Six trials (54.5%) demonstrated a discrepancy between the number of outcomes prespecified in the "Methods" and those reported in the "Results" (Table 4 Of the 74 cohort studies, seven (28, 31, 41, 47, 68, 70, 74 ) (9.5%) reported assessor details, none of whom were blinded. All eight longitudinal studies reported details of patient attrition. Twenty-eight articles (37.8%) demonstrated a discrepancy in outcome reporting between the methods and the results (Table 4 ). Overall, the cohort studies specified between zero and 16 complications in the methods (median = 3.5, IQR = 1.0 -6.3), but reported between one and 28 complications (median = 6.0, IQR = 5.0-9.0) in the results (P < .001, Wilcoxon signed rank test; Table 4 ). Consecutive patients were recruited in 49 studies (66.2%). Twenty studies (27.0%) disclosed funding sources, all of which were noncommercial. Institutional review board approval was reported in 12 studies (16.2%) and only one (1.4%) study reported a statistical power calculation (Table 4) . Of the 49 case series, six (101,108,119,123,140,141) (12.2%) reported assessor details, none of whom were blinded (Table 4) . Nine (81.8%) of the 11 longitudinal studies reported details of patient attrition. There was discrepancy between the number of outcomes reported in the methods and the results in 37 studies (75.5%). Overall, the case series studies specified between zero and 10 outcomes in the methods (median = 0, IQR = 0-2.0), but reported between zero and 20 complications (median = 7.0, IQR = 5.0-9.5) in the results (P <.001, Wilcoxon signed rank test). Outcomes from consecutive patients were reported in 27 studies (55.1%). Nineteen studies (38.8%) reported sources of funding, nine of which were from commercial sources (47.4%). Four studies (8.2%) were reviewed by an institutional review board, but none of the studies provided a statistical power calculation (Table 4) .
Outcome Reporting
Complications were defined by 87 (64.9%) studies and graded by 78 (58.2%) ( Table 5 ). The number of complications defined ranged from zero to 11 with a median of 1.0 (IQR = 0.0-1.3) per study. Important details such as the duration of follow-up and risk factors for adverse outcomes were omitted from 47 (35.1%) and 58 (43.3%) studies, respectively. Data relating to length of stay (n = 109 studies, 81.3%) and total complication rates (n = 80 studies, 59.7%) were frequently omitted. Only half the studies (n = 76) considered risk factors such as obesity and smoking in the analyses (Table 5) .
None of the study designs consistently fulfilled all of the published criteria (8) for outcome reporting. Fifty-three percent of studies demonstrated a disparity between methods and results in the numbers of complications reported. The severity of complications was more frequently graded in RCTs (P = .025, x 2 test), and RCTs and cohort studies defined significantly more outcomes than case series (P = .019). Cohort studies were significantly more likely to consider potential risk factors (P < .001), and case series were significantly more likely to report the duration of follow-up (P = .019). No differences were identified with respect to the reporting frequency of total (P = .326) or procedure-specific (P = .232) complications or length of stay (P = .741) data between study designs (Table 5) .
We analyzed the complications reported in over 20% of the articles in detail (Figure 2 ). These included four general complications that were reported for all types of reconstruction (infection, hematoma, seroma, and mastectomy skin flap loss and/or necrosis) and procedure-specific complications including capsular contracture, implant loss, and implant rupture for implant-based reconstructions and flap loss, fat necrosis, anastomotic complications, and donor site problems, including contour abnormalities and wound breakdown for abdominal flap procedures. Proportionally fewer studies (35, 25 .4%) evaluated the outcome of latissimus dorsi flap reconstructions, and donor site wound breakdown was the only procedure-specific complication identified for this reconstruction type. However, none of the identified studies defined this outcome ( Figure 2) . Overall, the studies defined fewer than 20% of the complications they reported, and the definitions were largely inconsistent. One hundred and thrity four articles reported a total of 950 complications, of which only 183 (19.3%) were defined. The studies only provided full definitions for a small number of the complications that they reported. Some complications such as capsular contracture (148) were frequently and consistently defined, whereas others such as fat necrosis and infection were defined inconsistently (Table 6) .
Discussion
This systematic review indicates that clinical outcome reporting in breast reconstruction is inconsistent and lacks methodological rigor. Less than 65% of articles provided definitions for the reported outcomes, and those described were often inconsistent, thus precluding cross-study comparisons. Details such as the severity of complications (41.8% of all studies), duration of follow-up (58.2%), and overall complication rates (59.7%) were often omitted. Only half the studies identified considered risk factors for adverse outcomes in their analyses. In addition, a high proportion of articles suffered from methodological issues such as selective outcome reporting (53.0%), potential selection bias (38.8%), and lack of blinding (99.3%). The RCTs evaluated did not report adequate methods for random sequence generation or allocation concealment in more than 80% of cases.
Previous work has summarized the inconsistency and limitations of morbidity reporting and its impact on the evaluation of surgical procedures (8) . The complication grading systems subsequently introduced (149) (150) (151) (152) (153) have been pivotal in improving the quality and consistency of outcome reporting in gastrointestinal cancer and have been shown to be valid and applicable worldwide in many fields of surgery (154) . These grading systems are yet to be used in breast reconstruction and may also improve reporting standards in this setting.
Survey data (6, 155, 156) suggest that women considering breast reconstruction would like as much information as possible for decision making, and the most useful information may come from RCTs, which provide the best evidence of outcomes (157) . Clinical trials in surgery are gaining in popularity, but they present challenges, particularly with respect to recruitment (158) due to patients' and surgeons' preferences for particular reconstruction types (159, 160) , standardization of treatment (158) , timing (161) , and blinding (160, 161) . However, RCTs in breast reconstruction have been described as "unethical" (25, 162, 163) , "impractical" (163, 164) , and "impossible" (48, 165, 166) , and only three trials have assessed the impact of the type (14, 167) and timing (168) of reconstructive surgery.
Despite strongly held views regarding the "impossibility" of RCTs comparing types of breast reconstruction, however, no studies exploring potential barriers to such trials have ever been undertaken. It is necessary to consult with both patients and surgeons to determine what kinds of trials would be potentially acceptable to them, for example, trials with random assignment comparisons of different implant-based procedures or comparisons of different types of flap. Such trials would be complex and would require extensive collaboration among methodologists, patients, and surgeons and possibly a feasibility phase to establish recruitment methods. Studies such as Prostate Testing for Cancer and Treatment (169) have demonstrated that embedding qualitative research in RCTs can dramatically improve both the design and the conduct of "difficult" trials, and this approach would be essential for any potential breast reconstruction RCT.
Another major challenge in the design of a successful RCT is the selection of appropriate outcome measures. Outcomes need to be valid and consistent to allow cross-study comparison and to facilitate meta-analyses (170) . The members of the Outcome Measures in Rheumatology (OMERACT) Group (http://www .omeract.org/)were among the first to recognize this problem and have developed "core outcome sets" for specific conditions to improve the quality and value of clinical trials and longitudinal research. Core outcome sets include outcomes that are important to both patients and health-care professionals. The OMERACT group uses a "data driven, iterative alignment process" (170) to select measures that satisfy the criteria of the OMERACT filter-truth, discrimination, and feasibility (171) . Several approaches for obtaining a consensus when defining core outcome sets have been described (172) , but involvement of all stakeholders in the process is vital to ensure that the selected outcomes are truly important. For interventions such as breast reconstruction where the ultimate aim is to improve cosmesis and quality of life, encompassing the patients' perspective would be essential. Traditional clinical outcomes remain important, but patient-reported outcomes such as satisfaction, body image, functional results, and cosmetic outcome will also need to be incorporated if the outcomes selected are to be of value to women making decisions about reconstruction. This review has indicated the need for a standardized approach to outcome assessment in breast reconstruction, and the rigorous development of a meaningful core outcome set may improve the consistency and value of outcome assessment after reconstructive surgery. In situations where clinical trials are challenging, it is necessary to use other sources of outcome data, such as prospective studies, to inform decision making. In the United Kingdom, the National Mastectomy and Breast Reconstruction Audit aims to investigate "the determinants and outcomes of care for women with breast cancer having a mastectomy with or without breast reconstruction" (173, 174) . The audit, which commenced in January 2007, has captured prospective data for 17 059 women undergoing mastectomy and/or breast reconstruction in England (173, 174) . The audit, which includes demographic, comorbidity, surgical, histological, and treatment data, as well as in-hospital complications, represents the largest evaluation of outcomes in breast reconstruction worldwide. It will therefore be an important resource for informing practice.
This review has several limitations. First, restricting the review to RCTs and large cohort studies and case series (n > 100) may have excluded important information. Larger studies are more likely to originate from high-volume centers and surgeons with a specific interest and, therefore, data may not be representative. These centers would be expected to benefit from additional resources, including staff trained in outcome assessment who could collect accurate outcome data prospectively and maintain dedicated databases. A comprehensive electronic search as well as a detailed hand search were performed; but, given the nature of the literature, it is possible that some relevant articles were omitted. Restricting the search to English language articles may also have led to some potentially useful studies being missed. Because this is a methodological review, the 134 studies included are likely to represent an adequate sample of the literature. However, the restrictions imposed by the inclusion criteria and the search strategy mean that the included studies are likely to have presented a more favorable picture of outcome reporting than if broader criteria have been used. As we have shown, even these studies showed limitations in how outcomes are reported (175).
This review has identified the need for a standardized approach to outcome reporting in breast reconstruction. At present, the breast reconstruction outcome literature is inconsistent and lacks methodological rigor. The rigorous development of a "core outcome set" for breast reconstruction is recommended to facilitate standardization of outcome reporting and study comparability and to increase the potential value of research for both patients and surgeons (176). Table 6 . Inconsistency of morbidity reporting after breast reconstruction*
Complication Definition
Fat necrosis Volume At least 10% of transverse rectus abdominus flap (n = 5) At least 1 cm in diameter (n = 2) Any clinically evident area of firmness (n = 6) Mild <5%, moderate 5-20%, severe >20% (n = 1) Subcutaneous firmness of 2-5 cm in diameter (n = 1) Negligible (≤1 cm 2 ), minor (<3 cm 2 ), moderate (>3 cm 2 but <7.5 cm 2 ) (n = 1) Induces major disfigurement of the reconstructed breast or patient dissatisfaction (n = 1) No matter how trivial (n = 1) <10% of breast volume (minor fat necrosis) (n = 1) Timing Up to 12 mo after surgery (n = 5) Persisting beyond 1 y (n = 7) Persisting beyond 3 mo after surgery (n = 2) Persisting beyond 6 mo after surgery (n = 1) Diagnosis A palpable area of firmness determined Not to be recurrent cancer (n = 1) Whether or not it was radiologically or pathologically confirmed (n = 6) An area of thickening, firmness, irregularity, or a draining sinus (n = 1) A localized area of firmness in the absence of wound healing problems (n = 1) Firmness in the flap post-operatively that did not resolve in 3 months (n = 1) Firm nodule which persisted more than 6 months (n = 1) Detected on office examination or found during revision surgery (n = 2) Treatment Whether or not it required further intervention (fine needle aspiration or excision) (n = 6); requiring re-operation because of surgeon's or patient's preference (n = 1) Requiring excision (n = 1) Partial flap loss Volume >10% (n = 4) >25% or >7.5 cm 2 (n = 1) 30% (n = 1) <30% (n = 1) "loss of a portion of the skin paddle" (n = 2) <50% (n = 1) Treatment Does not require additional surgery (n = 1) Responds to debridement and revision and still allows satisfactory reconstruction (n = 1) Infection Diagnostic criteria Clinical symptoms that resolved with antibiotics (n = 11) Culture proven infection requiring intravenous antibiotics or surgery (n = 1) Based on CDC 1992 definition (n = 2) Treatment required Hospitalization required for intravenous antibiotics (n = 10) Requiring inpatient or outpatient antibiotics (n = 1)
Abdominal hernia
An abdominal fascial defect (n = 2) A true hernia or abdominal wall laxity for which surgical repair is recommended (n = 4) Confirmed at the time of operative repair (n = 2) * CDC = Centers for Disease Control.
